# Lifecore Biomedical, Inc. \\de\\: financial statements, quarterly

LFCR · Nasdaq · CIK 1005286 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 25

Pages: [Overview](/companies/lfcr.md) · [Financials](/companies/lfcr/financials.md) · [Filings](/companies/lfcr/filings.md) · [Insiders](/companies/lfcr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lfcr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-05-28) | Q1 FY2024 (2023-08-27) | Q2 FY2024 (2023-11-26) | Q3 FY2024 (2024-02-25) | Q4 FY2024 (2024-05-26) | Q1 FY2025 (2024-08-25) | Q2 FY2025 (2024-11-24) | Q3 FY2025 (2025-02-23) | Q4 FY2025 (2025-05-25) | Q1 FY2026 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [31.1](/filings/0001005286-24-000030.md) | [24.5](/filings/0001005286-24-000145.md) | [30.2](/filings/0001005286-25-000012.md) | [35.7](/filings/0001005286-25-000055.md) | [37.9 d](/filings/0001005286-26-000009.md) | [24.7](/filings/0001005286-25-000148.md) | [32.6](/filings/0001005286-25-000012.md) | [35.2](/filings/0001005286-26-000020.md) | [36.4](/filings/0001005286-26-000033.md) | [31.1](/filings/0001005286-25-000148.md) | [23.2](/filings/0001005286-26-000020.md) | [34.2](/filings/0001005286-26-000033.md) |
| Cost of revenue | $m | [23.4 d](/filings/0001005286-24-000124.md) | [21.8](/filings/0001005286-24-000145.md) | [20.2](/filings/0001005286-25-000012.md) | [23.8](/filings/0001005286-25-000055.md) | [20.6 d](/filings/0001005286-26-000009.md) | [19.3](/filings/0001005286-25-000148.md) | [21.5](/filings/0001005286-25-000012.md) | [25.3](/filings/0001005286-26-000020.md) | [22.5](/filings/0001005286-26-000033.md) | [23.3](/filings/0001005286-25-000148.md) | [18.7](/filings/0001005286-26-000020.md) | [22.1](/filings/0001005286-26-000033.md) |
| Gross profit | $m | [7.8](/filings/0001005286-24-000030.md) | [2.7](/filings/0001005286-24-000145.md) | [10.0](/filings/0001005286-25-000012.md) | [11.9](/filings/0001005286-25-000055.md) | [17.3 d](/filings/0001005286-26-000009.md) | [5.4](/filings/0001005286-25-000148.md) | [11.1](/filings/0001005286-25-000012.md) | [9.8](/filings/0001005286-26-000020.md) | [14.0](/filings/0001005286-26-000033.md) | [7.8](/filings/0001005286-25-000148.md) | [4.5](/filings/0001005286-26-000020.md) | [12.1](/filings/0001005286-26-000033.md) |
| Research and development | $m | [2.1 d](/filings/0001005286-24-000124.md) | [2.1](/filings/0001005286-24-000145.md) | [2.1](/filings/0001005286-25-000012.md) | [2.2](/filings/0001005286-25-000055.md) | [2.2 d](/filings/0001005286-26-000009.md) | [2.2](/filings/0001005286-25-000148.md) | [1.9](/filings/0001005286-25-000012.md) | [2.0](/filings/0001005286-26-000020.md) | [2.1](/filings/0001005286-26-000033.md) | [2.0](/filings/0001005286-25-000148.md) | [1.2](/filings/0001005286-26-000020.md) | [1.5](/filings/0001005286-26-000033.md) |
| Selling, general and administrative | $m | [12.3 d](/filings/0001005286-24-000124.md) | [9.2](/filings/0001005286-24-000145.md) | [9.3](/filings/0001005286-25-000012.md) | [9.8](/filings/0001005286-25-000055.md) | [12.2 d](/filings/0001005286-26-000009.md) | [14.8](/filings/0001005286-25-000148.md) | [11.1](/filings/0001005286-25-000012.md) | [10.0](/filings/0001005286-26-000020.md) | [9.0](/filings/0001005286-26-000033.md) | [8.9](/filings/0001005286-25-000148.md) | [7.9](/filings/0001005286-26-000020.md) | [8.0](/filings/0001005286-26-000033.md) |
| Operating income | $m | [(6.6) d](/filings/0001005286-24-000124.md) | [(8.6)](/filings/0001005286-24-000145.md) | [(1.5)](/filings/0001005286-25-000012.md) | [(0.9)](/filings/0001005286-25-000055.md) | [2.1 d](/filings/0001005286-26-000009.md) | [(11.6)](/filings/0001005286-25-000148.md) | [(2.0)](/filings/0001005286-25-000012.md) | [(9.0)](/filings/0001005286-26-000020.md) | [5.3](/filings/0001005286-26-000033.md) | [(3.1)](/filings/0001005286-25-000148.md) | [(4.7)](/filings/0001005286-26-000020.md) | [2.6](/filings/0001005286-26-000033.md) |
| Interest expense | $m | [3.9 d](/filings/0001005286-24-000030.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.2 d](/filings/0001005286-24-000124.md) | [0.1](/filings/0001005286-24-000145.md) | [(0.1)](/filings/0001005286-25-000012.md) | [0.2](/filings/0001005286-25-000055.md) | [(0.1) d](/filings/0001005286-26-000009.md) | [(0.0)](/filings/0001005286-25-000148.md) | [0.0](/filings/0001005286-25-000012.md) | [(0.0)](/filings/0001005286-26-000020.md) | [0.0](/filings/0001005286-26-000033.md) | [0.3](/filings/0001005286-25-000148.md) | [0.0](/filings/0001005286-26-000020.md) | [0.0](/filings/0001005286-26-000033.md) |
| Net income | $m | [(39.3) d](/filings/0001005286-24-000124.md) | [(10.8)](/filings/0001005286-25-000012.md) | [14.2](/filings/0001005286-25-000012.md) | [15.6](/filings/0001005286-25-000055.md) | [(7.1) d](/filings/0001005286-26-000009.md) | [(16.2)](/filings/0001005286-25-000148.md) | [(6.6)](/filings/0001005286-25-000012.md) | [(14.8)](/filings/0001005286-26-000020.md) | [(1.1)](/filings/0001005286-26-000033.md) | [(10.0)](/filings/0001005286-25-000148.md) | [(15.0)](/filings/0001005286-26-000020.md) | [(6.2)](/filings/0001005286-26-000033.md) |
| Diluted EPS | $ per share | [(1.32)](/filings/0001005286-24-000030.md) | [(0.35)](/filings/0001005286-24-000145.md) | [0.39](/filings/0001005286-25-000012.md) | [0.42](/filings/0001005286-25-000055.md) | not reported | [(0.53)](/filings/0001005286-25-000148.md) | [(0.25)](/filings/0001005286-25-000012.md) | [(0.42)](/filings/0001005286-26-000020.md) | [(0.06)](/filings/0001005286-26-000033.md) | [(0.29)](/filings/0001005286-25-000148.md) | [(0.43)](/filings/0001005286-26-000020.md) | [(0.19)](/filings/0001005286-26-000033.md) |
| Basic EPS | $ per share | [(1.32)](/filings/0001005286-24-000030.md) | [(0.35)](/filings/0001005286-24-000145.md) | [0.47](/filings/0001005286-25-000012.md) | [0.51](/filings/0001005286-25-000055.md) | not reported | [(0.53)](/filings/0001005286-25-000148.md) | [(0.25)](/filings/0001005286-25-000012.md) | [(0.42)](/filings/0001005286-26-000020.md) | [(0.06)](/filings/0001005286-26-000033.md) | [(0.29)](/filings/0001005286-25-000148.md) | [(0.43)](/filings/0001005286-26-000020.md) | [(0.19)](/filings/0001005286-26-000033.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-11-26) | Q3 FY2024 (2024-02-25) | FY2024 (2024-05-26) | Q1 FY2025 (2024-08-25) | Q2 FY2025 (2024-11-24) | Q3 FY2025 (2025-02-23) | FY2025 (2025-05-25) | period not labelled (2025-06-30) | Q1 FY2026 (2025-09-30) | FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.2](/filings/0001005286-24-000111.md) | [3.1](/filings/0001005286-24-000112.md) | [8.5](/filings/0001005286-26-000009.md) | [5.5](/filings/0001005286-24-000145.md) | [9.5](/filings/0001005286-25-000012.md) | [5.4](/filings/0001005286-25-000055.md) | [8.3](/filings/0001005286-26-000009.md) | not reported | [18.9](/filings/0001005286-25-000148.md) | [17.5](/filings/0001005286-26-000033.md) | [20.8](/filings/0001005286-26-000020.md) | [17.2](/filings/0001005286-26-000033.md) |
| Current assets | $m | [76.7](/filings/0001005286-24-000111.md) | [76.2](/filings/0001005286-24-000112.md) | [81.0](/filings/0001005286-26-000009.md) | [74.2](/filings/0001005286-24-000145.md) | [81.9](/filings/0001005286-25-000012.md) | [84.2](/filings/0001005286-25-000055.md) | [85.7](/filings/0001005286-26-000009.md) | not reported | [83.9](/filings/0001005286-25-000148.md) | [82.3](/filings/0001005286-26-000033.md) | [77.6](/filings/0001005286-26-000020.md) | [83.7](/filings/0001005286-26-000033.md) |
| Total assets | $m | [246](/filings/0001005286-24-000111.md) | [246](/filings/0001005286-24-000112.md) | [254](/filings/0001005286-26-000009.md) | [247](/filings/0001005286-24-000145.md) | [255](/filings/0001005286-25-000012.md) | [238](/filings/0001005286-25-000055.md) | [239](/filings/0001005286-26-000009.md) | not reported | [235](/filings/0001005286-25-000148.md) | [232](/filings/0001005286-26-000033.md) | [225](/filings/0001005286-26-000020.md) | [230](/filings/0001005286-26-000033.md) |
| Current liabilities | $m | [40.3](/filings/0001005286-24-000111.md) | [36.8](/filings/0001005286-24-000112.md) | [38.9](/filings/0001005286-26-000009.md) | [40.5](/filings/0001005286-24-000145.md) | [35.3](/filings/0001005286-25-000012.md) | [31.1](/filings/0001005286-25-000055.md) | [30.2](/filings/0001005286-26-000009.md) | not reported | [30.0](/filings/0001005286-25-000148.md) | [23.6](/filings/0001005286-26-000033.md) | [20.5](/filings/0001005286-26-000020.md) | [21.6](/filings/0001005286-26-000033.md) |
| Total liabilities | $m | [203](/filings/0001005286-24-000111.md) | [187](/filings/0001005286-24-000112.md) | [200](/filings/0001005286-26-000009.md) | [207](/filings/0001005286-24-000145.md) | [196](/filings/0001005286-25-000012.md) | [190](/filings/0001005286-25-000055.md) | [192](/filings/0001005286-26-000009.md) | not reported | [198](/filings/0001005286-25-000148.md) | [198](/filings/0001005286-26-000033.md) | [205](/filings/0001005286-26-000020.md) | [213](/filings/0001005286-26-000033.md) |
| Long-term debt | $m | [92.1](/filings/0001005286-24-000111.md) | [96.3](/filings/0001005286-24-000112.md) | [101](/filings/0001005286-25-000012.md) | [106](/filings/0001005286-24-000145.md) | [111](/filings/0001005286-25-000012.md) | [125](/filings/0001005286-25-000055.md) | [130](/filings/0001005286-26-000009.md) | not reported | [136](/filings/0001005286-25-000148.md) | [142](/filings/0001005286-26-000033.md) | [149](/filings/0001005286-26-000020.md) | [155](/filings/0001005286-26-000033.md) |
| Current portion of debt | $m | [0.8](/filings/0001005286-24-000111.md) | [0.8](/filings/0001005286-24-000112.md) | [0.9](/filings/0001005286-26-000009.md) | [0.8](/filings/0001005286-24-000145.md) | [0.8](/filings/0001005286-25-000012.md) | [0.9](/filings/0001005286-25-000055.md) | [3.4](/filings/0001005286-26-000009.md) | not reported | [0.9](/filings/0001005286-25-000148.md) | [1.0](/filings/0001005286-26-000033.md) | [1.0](/filings/0001005286-26-000020.md) | [1.0](/filings/0001005286-26-000033.md) |
| Shareholders' equity | $m | [1.4](/filings/0001005286-25-000055.md) | [17.7](/filings/0001005286-25-000055.md) | [11.3](/filings/0001005286-26-000009.md) | [(3.9)](/filings/0001005286-25-000148.md) | [15.4](/filings/0001005286-26-000033.md) | [2.2](/filings/0001005286-26-000033.md) | [1.3](/filings/0001005286-26-000033.md) | [(0.9)](/filings/0001005286-25-000148.md) | [(10.5)](/filings/0001005286-25-000148.md) | [(14.2)](/filings/0001005286-26-000033.md) | [(28.4)](/filings/0001005286-26-000033.md) | [(34.1)](/filings/0001005286-26-000033.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-05-28) | Q1 FY2024 (2023-08-27) | Q2 FY2024 (2023-11-26) | Q3 FY2024 (2024-02-25) | Q4 FY2024 (2024-05-26) | Q1 FY2025 (2024-08-25) | Q2 FY2025 (2024-11-24) | Q3 FY2025 (2025-02-23) | Q4 FY2025 (2025-05-25) | Q1 FY2026 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,262) d](/filings/0001005286-24-000124.md) | [(8,329)](/filings/0001005286-24-000145.md) | [1,288 d](/filings/0001005286-25-000012.md) | [(1,418) d](/filings/0001005286-25-000055.md) | [8,716 d](/filings/0001005286-26-000009.md) | [(613)](/filings/0001005286-25-000148.md) | [(6,140) d](/filings/0001005286-25-000012.md) | [1,199](/filings/0001005286-26-000020.md) | [5,347 d](/filings/0001005286-26-000009.md) | [1,762](/filings/0001005286-25-000148.md) | [4,700](/filings/0001005286-26-000020.md) | [(2,189) d](/filings/0001005286-26-000033.md) |
| Capital expenditure | $k | not reported | [5,054](/filings/0001005286-24-000145.md) | [4,261 d](/filings/0001005286-25-000012.md) | [6,367 d](/filings/0001005286-25-000055.md) | [2,713 d](/filings/0001005286-26-000009.md) | [3,422](/filings/0001005286-25-000148.md) | [2,440 d](/filings/0001005286-25-000012.md) | [5,456](/filings/0001005286-26-000020.md) | [2,097 d](/filings/0001005286-26-000009.md) | [1,737](/filings/0001005286-25-000148.md) | [1,118](/filings/0001005286-26-000020.md) | [513 d](/filings/0001005286-26-000033.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q2 FY2023 (2022-11-27) | Q3 FY2023 (2023-02-26) | Q1 FY2024 (2023-08-27) | Q2 FY2024 (2023-11-26) | Q3 FY2024 (2024-02-25) | Q1 FY2025 (2024-08-25) | Q2 FY2025 (2024-11-24) | Q3 FY2025 (2025-02-23) | Q4 FY2025 (2025-05-25) | Q1 FY2026 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [29.6](/filings/0001005286-24-000111.md) | [30.3](/filings/0001005286-24-000112.md) | [30.4](/filings/0001005286-24-000145.md) | [36.4](/filings/0001005286-25-000012.md) | [36.6](/filings/0001005286-25-000055.md) | [30.9](/filings/0001005286-25-000148.md) | [34.4](/filings/0001005286-25-000012.md) | [37.0](/filings/0001005286-26-000020.md) | [37.0](/filings/0001005286-26-000033.md) | [37.4](/filings/0001005286-25-000148.md) | [37.5](/filings/0001005286-26-000020.md) | [37.6](/filings/0001005286-26-000033.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,853,060 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001005286-26-000033.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.